Clinical trials: Concentration
Cholestasis
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
In participants with inadequate response/intolerance to ursodeoxycholic acid (UDCA) taking obeticholic acid (OCA) who experience pruritus (due to primary biliary cholangitis [PBC], OCA, or both) the addition of linerixibat to OCA…
- Trial name
- NCT04053023
- Testing
- GSK2330672 (linerixibat), Obeticholic acid
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to gain initial safety, tolerability, pharmacokinetic, and efficacy information on SPD489 in preschool children 4-5 years old who are diagnosed with ADHD.
- Trial name
- NCT02402166
- Testing
- SPD489
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire
ADHD
Lifestyle Enhancement for ADHD Program
The purpose of this study is to investigate if physical activity (PA) can increase in children with Attention Deficit/Hyperactivity Disorder (ADHD) using a modified behavioral management training (BMT) program.
- Trial name
- LEAP (NCT03690674)
- Testing
- Lifestyle Enhancement for ADHD Program
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Dental Fluorosis, Dental Caries
Effect of pH and Fluoride Concentration of Dentifrices on Caries Control
This study aims to assess the overall effect of pH and fluoride concentration of liquid dentifrices in the control of children dental caries of a fluoridated area, through visual inspection and the quantitative light-induced…
- Trial name
- EPHFCDCC (NCT01049503)
- Testing
- Low fluoride and conventional dentifrices with different pH
- Where
- Brazil
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Conduct Disorder, Oppositional Defiant Disorder
Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits
The purpose of this study is to modify behavior therapy so that it is optimized for children with conduct problems and callous-unemotional traits by emphasizing reward components and de-emphasizing punishment components.
- Trial name
- NCT01362946
- Testing
- Reward-Emphasized Treatment, Standard Treatment
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Florida International University
Persian Gulf Syndrome
Mindfulness-Based Stress Reduction for Gulf War Syndrome
This pilot study is a two arm randomized, controlled clinical trial that evaluated whether a standardized Mindfulness-Based Stress Reduction (MBSR) intervention reduces symptoms associated with Gulf War Syndrome (GWS) more…
- Trial name
- NCT01267045
- Testing
- Mindfulness-based stress reduction
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- US Department of Veterans Affairs
Immunogenicity, Vaccine
A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS
This is a PAC study after PCV13 launch in China. Based on recommendation from China Agency, Pfizer was required to conduct a descriptive immunogenicity study to measure the antibody levels at the time of disease onset.
- Trial name
- NCT05372575
- Testing
- PCV13 PAC study
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
ADHD
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months
- Trial name
- NCT00784654
- Testing
- Lisdexamfetamine dimesylate (LDX)
- Where
- 51 sites in United States, Belgium and 7 more
- Volunteers
- 276 people
- Sponsor
- Shire
Attention-Deficit Hyperactivity Disorder (ADHD)
PDC-1421 Treatment in Adult Patients With ADHD
Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.
- Trial name
- NCT05202327
- Testing
- PDC-1421 Capsule
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 99 people
- Sponsor
- BioLite, Inc.
Androgenetic Alopecia
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey, will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male androgenetic…
- Trial name
- NCT03742518
- Testing
- Topical SM04554 0.15% solution, Topical SM04554 0.25% solution, Topical vehicle solution
- Where
- 14 sites in Turkey (Türkiye)
- Volunteers
- 675 people
- Sponsor
- Biosplice Therapeutics, Inc.
Attention Deficit Hyperactivity Disorder
A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
The main purpose of the study is to help to understand the effect on children and adolescents who are stable on treatment with atomoxetine or osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity…
- Trial name
- EMD (NCT01127646)
- Testing
- Atomoxetine, Osmotic-release oral system methylphenidate
- Where
- 14 sites in Netherlands, Spain and 1 more
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder
Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
A three-arm, randomized, double-blind, placebo-controlled, Phase 4, multicenter study to compare the efficacy and safety of atomoxetine versus placebo in children and adolescents aged 6 through 17 years with…
- Trial name
- NCT00406354
- Testing
- Atomoxetine
- Where
- 6 sites in Germany
- Volunteers
- 181 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
Treatment of Severe Childhood Aggression (The TOSCA Study)
This study will determine the safety and effectiveness of two medications for treating aggression in children with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00796302
- Testing
- Methylphenidate HCl, Risperidone, Parent Management Training (PMT)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- Michael Aman
Attention Deficit Hyperactivity Disorder
A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
The purpose of this study is to assess long-term safety and tolerability in adult patients who have completed a previous atomoxetine study.
- Trial name
- NCT00969618
- Testing
- Atomoxetine
- Where
- 12 sites in Japan
- Volunteers
- 211 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
A double-blind, placebo controlled study of solriamfetol for adults age 18 to 65 with diagnosis of Attention Deficit Hyperactivity Disorder.
- Trial name
- NCT04839562
- Testing
- Solriamfetol 75 MG, Solriamfetol 150 MG
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
This Phase 3 pivotal efficacy trial will examine the effects of HLD200 (methylphenidate) in patients aged 6-12 years with ADHD in a laboratory classroom setting.
- Trial name
- NCT02493777
- Testing
- HLD200 methylphenidate hydrochloride (MPH) Capsules
- Where
- 7 sites in United States
- Volunteers
- 125 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
Relative Bioavailability, AUC
Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions
This study is a randomized, open-label, cross-over study in healthy subjects performed at a single study center. The study is divided into two parts, Part 1 and Part 2.
- Conditions
- Relative Bioavailability, AUC, Cmax, Pharmacokinetics
- Trial name
- NCT02359045
- Testing
- D1400147, D14000136, D14000137
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Magnetic Resonance Imaging, Cognition
Nicotinic Modulation of the Default Network
Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and schizophrenia, display abnormal regulation of the so-called default network of resting brain function that maintains internally directed…
- Conditions
- Magnetic Resonance Imaging, Cognition, Nicotine, Mecamylamine
- Trial name
- NCT01223404
- Testing
- Nicotine, Mecamylamine
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Attention-Deficit/Hyperactivity Disorder (ADHD)
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- ADHD (NCT04786990)
- Testing
- SPN-812
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 96 people
- Sponsor
- Supernus Pharmaceuticals, Inc.